Hyderabad, 4 May 2024: Aurobindo Pharma, on Friday, May 3, said it has received seven observations from the United States Food and Drug Administration ( US FDA) for its unit-II formulation manufacturing facility located in Bhiwadi, Rajasthan.

 

The FDA conduc......
View Details

Related News

• Public Advisory issued for Counterfeit ‘Pulmosil Injection’ containing Fungus by DCA Telangana (18-05-2024)

---

• Interim stay on order suspending manufacture of 14 Patanjali drugs: Official (18-05-2024)

---

• Another Baddi firm loses product licence (18-05-2024)

---

• Health ministry plans central online drug registry to avoid medication error caused by similar names (18-05-2024)

---

• Bombay HC rejects bail plea of two booked for smuggling 10.5 lakh Tramadol tablets, grants relief to courier manager (18-05-2024)

---

• DCGI seeks list of licensed Antibiotic combinations from State LAs (18-05-2024)

---

• Medical device companies get a three-month extension for licences (18-05-2024)

---

• Banned cough syrup seized from Assam-Tripura border (18-05-2024)

---

• WHO updates list of drug-resistant bacteria most threatening to human health (17-05-2024)

---

• DCA Telangana continue action on overpriced medicines, adulterated Ayur Medicine, misleading claims and quack's clinic (17-05-2024)

---